Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Safety and efficacy of idasanutlin in PV

Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, reports the results of the Phase II study (NCT03287245) of idasanutlin, an inhibitor of MDM2 which causes P53 activation in patients with hypoxyurea resistant/intolerant polycythemia vera. Although the inhibitor has demonstrated profound efficiency and therapeutic effect, low-grade gastrointestinal toxicity was observed which could not be managed effectively. Dr Yacoub goes on to discuss future directions for utilizing the novel therapy to serve patients experiencing this toxicity. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.